Table 1.
GOUT-H participants characteristics
| Characteristicsa | N = 34b |
|---|---|
| Age (years)b | 43 ± 13 (24–68) |
| Gender, malec | 31 (91%) |
| Height (cm)b | 160 ± 7 (146–179) |
| Weight (kg)b | 84 ± 17 (54–134) |
| BMI (kg/m2)b,d | 32.5 ± 5.5 (21.6–47.0) |
| Normalc | 1 (2.9%) |
| Overweightc,d | 4 (12%) |
| Obesityc, | 29 (85%) |
| Estimated CrCL (mL/min)b,e, | 87 ± 31 (25–165) |
| 15 ≤ Estimated CrCL < 30 | 1 (3%) |
| 30 ≤ Estimated CrCL < 60 | 8 (24%) |
| Estimated CrCL ≥ 60 | 25 (74%) |
| Baseline serum urate (mg/dL)b | 9.61 ± 1.67 (5.8–13.0) |
| Post-treatment serum urate (mg/dL)b | 5.4 ± 1.1 (3.1 – 7) |
| Steady-state serum oxypurinol0hr (mg/L)f | 10.6 [7.8, 16.3] (4.3–30.4) |
| Steady-state serum oxypurinol6hr (mg/L)f | 12.6 [9.4, 18.1] (6.4–28.4) |
| Self-reported medications related to SU/gout c,g | |
| Drugs that lower serum urate | 10 (29%) |
| Losartan | 1 (2.9%) |
| HMG-CoA inhibitors | 5 (15%) |
| Calcium channel blockers | 5 (15%) |
| Drugs that increase serum urate | 22 (65%) |
| Angiotensin converting enzyme inhibitors | 5 (15%) |
| Angiotensin receptor blockers (not losartan) | 1 (2.9%) |
| Beta-blockers | 6 (18%) |
| Diuretics | 4 (12%) |
| Non-steroidal anti-inflammatory drugs | 16 (47%) |
BMI, body mass index; CrCL, creatinine clearance; SU, serum urate
a
Characteristics were assessed at the baseline study visit after 10 days washout period.
b
Mean ± standard deviation (range)
c
n (%)
d
Overweight was defined as BMI 23.0–27.5 kg/m2; obesity was defined as BMI > 27.5 kg/m2 based on World Health Organization Asian criteria-based BMI52.
e
Estimated CrCL was calculated using Cockcroft-Gault Equation with adjusted body weight.
f
Median [interquartile range] (range)
g
Only medications that may impact serum urate are listed.